focus -WSS

focus

author：hotspot 2025-09-05 15:39:44 Page View：16

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The biotech scorecard for Q4: 16 stock
Next article： Tori Bowie and the unacceptable rates of Black maternal death

explore

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

30 years of 'Listening to Prozac'

WhenProzacfirstenteredthepsychiatrysceneininthelate’80s,theprofessionwasstillFreud’sterritory.Manyco

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

CourtesyUnitedHealthGroupUnitedHealthGrouphasabout90,000employedoraffiliateddoctors,approximately10%